ClinicalTrials.gg
CompletedNCT01504984Updated Jun 12, 2012

Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers

A Phase 1 interventional study of SYO-1126 and Glivec film coated tab 4T(400mg) in Healthy, sponsored by Samyang Biopharmaceuticals Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-12.

Sponsored by Samyang Biopharmaceuticals Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYO-1126 and Glivec Film Coated tab 4T (400mg) when administered a single-dose to healthy male volunteers.

Read the detailed description

Healthy volunteers are administrated single-dose over the period I and II (crossover) of SYO-1126 and Glivec Film Coated tab 4T (400mg) as of imatinib 400mg.

Every time before and after each medication, pharmacokinetic (PK) parameters and safety of SYO-1126 and Glivec Film Coated tab 4T (400mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.

02

Conditions studied

  • Healthy

Keywords

  • Evaluation of the pharmacokinetics equivalence
  • Healthy volunteers
  • Single dose over the period I and II(crossover)
  • Healthy male volunteers
03

In context

Lead sponsor

Samyang Biopharmaceuticals Corporation is the lead sponsor of 30 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 20aged and 45aged in healthy males
  • Over 55kg and : 18.5\~25 kg/m2
  • Agreement with written

Exclusion criteria

Exclusion Criteria:

  • Subject with symptoms of acute disease at the time of screening
  • cardiovascular system, pulmonary system, renal system, endocrine system, blood system, gastrointestinal system, nervous system, mental disease or malignant tumor
  • Subject with known for gastrointestinal disease or surgical history which affect on absorption of drug
  • An impossible one who participates in clinical trial by result of screening tests
  • Inadequate result of laboratory test /ALT > 1.5 x UNL Total > 1.5 X UNL
  • Clinically significant allergic disease(Except for mild allergic rhinitis seems to be not need for medication)
  • Subject with known for reaction to imatinib analog
  • Subject with known for history which drug abuse or show positive for it in screening tests
  • Previously participate in other trial within 60 days
  • Previously make whole blood donation within 60 days or component blood donation within 30 days
  • Previously have blood transfusion within 30 days
  • Not able to taking the institutional standard meal
  • Subject who have had abnormal eating which affect on the ADME of drug
  • Not able to taking the grapefruit-containing foods
  • Taking ETC(ethical the counter)medicine including oriental medicine within 14 days or taking OTC(over the counter)medicine or vitamin preparations within 7 days
  • Continued to be taking caffein(caffein>5cup/day), drinking (alcohol>30g/day) and severe heavy smoker(cigarette>1/2pack/day)
  • An impossible one who participates in clinical trial by investigator's decision including for reason laboratory test result
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SYO-1126

    Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

    Drug: SYO-1126

  • Active comparator
    Glivec film coated tab 4T(400mg)

    100mg/tablet, po, 4 tablets once daily for period I\&II D1(crossover)

    Drug: Glivec film coated tab 4T(400mg)

Interventions

  • Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

    Also known as: Imatinib 400mg

  • DrugGlivec film coated tab 4T(400mg)

    Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)

    Also known as: Imatinib 100mg, Glivec film coated tab

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of the AUCt SYO-1126 anf Glivec Film coated tab 4T(400mg)

    Time frame: 0-72hr

  2. Pharmacokinetics of the Cmax SYO-1126 anf Glivec Film coated tab 4T(400mg)

    Time frame: 0-72hr

Secondary outcomes

  1. Pharmacokinetics of the AUCinf SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

  2. Evaluation of the safety of SYO-1126 and Glivec Film Coated 4T(400mg) from vital signs, physical exam, ECG, laboratory test, adverse events and so on.

    Time frame: 20~24 days

  3. Pharmacokinetics of the Tmax of SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

  4. Pharmacokinetics of the T1/2 of SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

  5. Pharmacokinetics of the CL/F of SYO-1126 and Glivec Film Coated 4T(400mg)

    Time frame: 0-72hr

07

Study locations

1 site
  • Severance hospital
    Seoul, Seodaemun-gu, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2011
First posted
Jan 6, 2012
Start
Mar 2012
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Jun 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01504984
Collaborators
Severance Hospital
Responsible party
Sponsor
First posted
Jan 6, 2012
Start date
Mar 2012
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Jun 12, 2012

Study contacts

Min Su Park, Doctor
principal investigator · Severance Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion